<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="209950">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354432</url>
  </required_header>
  <id_info>
    <org_study_id>cccwfu97405</org_study_id>
    <secondary_id>CCCWFU-97405</secondary_id>
    <secondary_id>CCCWFU-BG05-529</secondary_id>
    <nct_id>NCT00354432</nct_id>
  </id_info>
  <brief_title>Soy Protein/Isoflavones and Venlafaxine in Treating Hot Flashes in Patients Receiving Hormone Therapy for Prostate Cancer</brief_title>
  <official_title>Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Soy protein/isoflavones and venlafaxine may help relieve hot flashes in patients
      receiving hormone therapy for prostate cancer. It is not yet known whether soy
      protein/isoflavones are more effective than venlafaxine when given together or with a
      placebo in treating hot flashes.

      PURPOSE: This randomized phase III trial is studying soy protein/isoflavones and venlafaxine
      to compare how well they work when given together or with a placebo in treating hot flashes
      in patients receiving hormone therapy for prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Assess the effect of soy protein/isoflavones and venlafaxine on the hot flash symptom
           severity score in patients undergoing hormonal manipulation for treatment of prostate
           cancer.

      Secondary

        -  Assess the effect of soy protein/isoflavones and venlafaxine on quality of life of
           these patients.

        -  Monitor and assess the participant drop out rate.

      OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified
      according to severity of disease (metastatic vs nonmetastatic) and baseline severity of hot
      flashes. Patients are randomized to 1 of 4 treatment arms.

        -  Arm I: Patients receive oral placebo pill and oral soy protein/isoflavones powder once
           daily.

        -  Arm II: Patients receive oral venlafaxine and oral placebo powder once daily.

        -  Arm III: Patients receive oral venlafaxine and oral soy protein/isoflavones powder once
           daily.

        -  Arm IV: Patients receive oral placebo pill and oral placebo powder once daily.
           Treatment in all arms continues for 12 weeks in the absence of disease progression or
           unacceptable toxicity. After 12 weeks of treatment, patients in arms I and III receive
           a tapered dose of oral venlafaxine once daily for 1 week.

      Patients complete a vasomotor symptom diary once daily beginning 7 days before the
      initiation of study treatment and continuing until the completion of study treatment.
      Quality of life is assessed at baseline and at week 12.

      PROJECTED ACCRUAL: A total of 176 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in the hot flash symptom severity score from baseline to 12 weeks</measure>
    <time_frame>12 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by FACT-P at baseline and at 12 weeks of treatment</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment regimens</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Hot Flashes</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral venlafaxine and oral placebo powder once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral venlafaxine and oral soy protein/isoflavones powder once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo pill and oral placebo powder once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soy isoflavones</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soy protein isolate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed prostate cancer

               -  Any stage disease allowed

          -  Undergoing or underwent androgen deprivation for treatment or control of prostate
             cancer including any of the following:

               -  Bilateral orchiectomy

               -  Luteinizing hormone-releasing hormone (LHRH) agonist therapy (e.g., leuprolide,
                  goserelin, bicalutamide, flutamide, or similar agents) with or without
                  antiandrogen therapy

               -  Chemotherapy

               -  Radiotherapy (patients may undergo concurrent radiotherapy to the prostate,
                  prostate and seminal vesicles, and/or pelvis)

                    -  Seed implants allowed

          -  Hot flash frequency ≥ 4 per day, as defined by sweating, flushing, sensation of
             warmth, night sweats

               -  Hot flashes must be moderated (grade 2) or severe (grade 3)

          -  Patient reports overall hot flash severity as moderate to severe

        PATIENT CHARACTERISTICS:

          -  Life expectancy ≥ 9 months

          -  Bilirubin &lt; 2 mg/dL

          -  AST ≤ 2 times normal

          -  Must have a telephone

          -  No allergies to soy or dairy products

          -  No uncontrolled hypertension (i.e., BP 160/90 mm Hg) or American Heart Association
             functional capacity ≥ class I

          -  No history of mania, hypomania, bipolar disorder, or anorexia nervosa

          -  No history of seizures

          -  No history of hepatic dysfunction

          -  No history of intolerance to venlafaxine

          -  No history of seizure disorder

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 14 days since prior venlafaxine, monoamine oxidase inhibitor (MAOI),
             selective serotonin reuptake inhibitor (SSRI), or selective norepinephrine reuptake
             inhibitor (SNRI)

          -  Prior and concurrent stable regimen of soy foods, or soy based supplements allowed

          -  Concurrent stable regimen of herbal supplements for hot flashes allowed

          -  No concurrent chemotherapy, radiotherapy, or surgery

          -  No concurrent estrogen, progestational agents, corticosteroids, androgens, or other
             medications (such as clonidine or bellamine) directed at alleviating hot flashes

          -  No concurrent SSRIs, SNRIs, MAOIs, or linezolide

          -  No concurrent medication to relieve hot flashes

          -  No other concurrent antidepressant therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mara Vitolins, DrPH, RD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - JHS Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern Indiana CR Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cedar Rapids Oncology Project</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - LSU Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feist-Weiller Cancer Center at Louisiana State University Health Sciences</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Michigan Cancer Research Consortium</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Beaumont</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073-6769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cancer Research for the Ozarks</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Heartland Research Consortium</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Louis-Cape Girardeau</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Cancer Center at Alamance Regional Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center - Goldsboro</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caldwell Memorial Hospital</name>
      <address>
        <city>Lenoir</city>
        <state>North Carolina</state>
        <zip>28645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University CCOP Research Base</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas - Easley</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Vincent Hospital Cancer Center, Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <lastchanged_date>June 26, 2012</lastchanged_date>
  <firstreceived_date>July 19, 2006</firstreceived_date>
  <responsible_party>
    <name_title>Edward G. Shaw</name_title>
    <organization>Wake Forest University Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>hot flashes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
